Regulatory issues of the genome-edited products after the ECJ judgement

1) As the European Commission, do you expect any policy actions at EU level in reaction to the ECJ judgment, such as changing any Directives or issuing any additional guidance?

- Do you have any predicted schedule of such actions, if any?
- Is there a possibility to reduce the requirements for risk assessment of the genome-edited organisms?

2) Do you have any observation regarding the Member States' and/or European Parliament's reaction after the ECJ judgement, such as introduction of additional measures for the mutagenesis?

3) We would like to know the regulatory status of the product of null segregant. Has the regulatory status of null segregant become clear based on the ECJ judgement?

4) Do you expect any impacts on research activities related to the genome editing, including safety of the genome editing and/or public acceptance, in research project funded by EU and Member States? Is there any survey on public perception about the genome editing in EU?

5) We would like to know how the border control could be installed for importation of the gene edited products, especially the products identical to conventional products, from overseas.

6) We understand that there will be an election of European Parliament next spring, and you will have new Commissioners in autumn later next year. Do you expect that this situation would affect the discussions on the regulatory issues related to the genome editing?